BeiGene Ltd. (BEIGF)
OTC PINK 
HKEX Primary OTC PINK Summary
BeiGene Ltd. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| JD Jim Dushek HARBOUR INVESTMENTS Inc. | 42 | $81.54 | $921.73 | $840.19 | 1,030.4% |
 Farallon Capital Farallon Capital Management LLC | 1,100 | $17,050 | $24,140.6 | $7,090.6 | 41.59% |
 John H. Burbank III Passport Capital LLC | 8.8M | $1.57B | $193.1M | -$1.38B | -87.71% |
| YA Yinka Akinsola Blue Trust Inc. | 826 | $13,174.7 | $18,127.4 | $4,952.7 | 37.59% |
 Kyle P. Smith NewEdge Wealth LLC | 1,827 | $26,189.37 | $40,095.34 | $13,905.97 | 53.1% |
BeiGene Ltd. (BEIGF) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has BeiGene Ltd. ever had a stock split?
BeiGene Ltd. Profile
| Biotechnology Industry | Healthcare Sector | Mr. John V. Oyler CEO | OTC PINK Exchange | 07725L102 CUSIP |
| CN Country | 10,600 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
BeiGene, Ltd. is a prominent player in the global healthcare sector, focusing on the development and commercialization of oncology medicines. This enterprise operates worldwide, demonstrating a strong commitment to providing innovative treatments for cancer patients. Since its inception in 2010, BeiGene has strategically positioned itself in the biopharmaceutical market, with a significant presence based in Grand Cayman, the Cayman Islands. The company’s operations extend through its various subsidiaries, all aligned towards a common goal of combating cancer. BeiGene's collaborative efforts with leading pharmaceutical and biotechnology companies underscore its dedication to advancing cancer treatment and research. Such partnerships enable the exchange of scientific knowledge and resources, facilitating the development of groundbreaking oncology medicines. BeiGene’s approach to cancer treatment is multifaceted, encompassing the production of a diverse range of oncology drugs designed to meet the varied needs of cancer patients globally.
Products and Services
- BRUKINSA - Designed to treat various blood cancers, offering hope and a new treatment avenue for patients.
- TEVIMBRA - Used in the treatment of solid tumor and blood cancers, showcasing BeiGene's versatility in addressing both blood and solid cancers.
- PARTRUVIX - Focuses on the treatment of solid tumor malignancies, adding to the arsenal against solid tumors.
- XGEVA - A specialized medicine for bone metastases from solid tumors and multiple myeloma, and for treating giant cell tumor of bone.
- BLINCYTO - Targets acute lymphoblastic leukemia, offering a critical solution for this aggressive cancer.
- KYPROLIS - Aids in the treatment of R/R multiple myeloma, providing a lifeline for patients with relapsed or refractory multiple myeloma.
- REVLIMID - Another key medicine for multiple myeloma, emphasizing BeiGene's focus on this cancer type.
- VIDAZA - Treats myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia, expanding the treatment options for leukemia patients.
- SYLVANT - Aimed at treating idiopathic multicentric Castleman disease, highlighting BeiGene's commitment to addressing rare diseases.
- QARZIBA - Focused on treating neuroblastoma, supporting the fight against cancer in children.
- POBEVCY - Used for metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC), showing the broad scope of BeiGene's oncology portfolio.
- BAITUOWEI - A solution for breast and prostate cancers, addressing some of the most common cancers worldwide.
- TAFINLAR and MEKINIST - These work in tandem to treat NSCLC and melanoma, reflecting the company's innovative approach in targeting specific cancer mutations.
- VOTRIENT - For advanced renal cell carcinoma, representing BeiGene's foray into kidney cancer treatment.
- AFINITOR - Treats advanced renal cell carcinoma, NET, SEGA, & breast cancers, showing the drug's versatility in combating a variety of cancers.
- ZYKADIA - Specifically targets ALK+ NSCLC, demonstrating BeiGene’s commitment to personalized cancer medicine.
Additionally, BeiGene is actively developing a range of inhibitors and antibodies, such as Sonrotoclax (BGB-11417), BGB-10188, and Zanidatamab, showcasing its ongoing efforts in expanding its oncology portfolio. Collaborations with entities like Shoreline Biosciences, Inc., Amgen Inc., and Bristol Myers Squibb company further solidify BeiGene's position as a leader in oncology research and drug development.
